The research project “Improved Tumor Targeting with Radiolabeled Peptidomimetics” with a 5-year duration (2018-2023) is coordinated by Dr. B. A. Nock. It concerns a research cooperation of the Molecular Radiopharmacy team with the Ludwig Boltzmann Institute Applied Diagnostics, sponsored by Austrian Science Foundation (FWF). The project aims at the development of new peptidomimetic-based radiopharmaceuticals, with focus on somatostatin analogs, for tumor targeting in human.